A recent report challenging the FDA's approval of mifepristone has ignited controversy, though the medication remains one of the most extensively reviewed and safely used drugs over 25 years. Critics argue the report is politically driven and methodologically flawed, threatening established regulatory frameworks that underpin biotech drug development and public health. The episode highlights ongoing tensions affecting perceptions of FDA oversight and drug approval integrity.